 Cellectar Biosciences Inc NASDAQ: CLRB has collaborated with LegoChemBio to develop and commercialize phospholipid drug conjugates PDCs. Under the agreement, the two companies have the option to jointly develop three new small molecule PDCs utilizing Cellectars drug targeting platform, phospholipid ether technology, and LegoChemBios proprietary drug conjugate linker-toxin platform. 